Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-03-22
2011-03-22
Noakes, Suzanne M (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S174000, C435S069100, C435S069700, C435S004000, C435S007210, C435S007710, C435S007800, C435S007930, C435S035000, C514S002600, C514S008100, C514S021800
Reexamination Certificate
active
07910698
ABSTRACT:
The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.
REFERENCES:
patent: 5306817 (1994-04-01), Thiruvengadam et al.
patent: 5561227 (1996-10-01), Thiruvengadam et al.
patent: 5618707 (1997-04-01), Homann et al.
patent: 5624920 (1997-04-01), McKittrick et al.
patent: 5627176 (1997-05-01), Kirkup et al.
patent: 5631365 (1997-05-01), Rosenblum et al.
patent: 5633246 (1997-05-01), McKittrick et al.
patent: 5656624 (1997-08-01), Vaccaro et al.
patent: 5661145 (1997-08-01), Davis
patent: 5688785 (1997-11-01), Vaccaro
patent: 5688787 (1997-11-01), Burnett et al.
patent: 5688990 (1997-11-01), Shankar
patent: 5698548 (1997-12-01), Dugar et al.
patent: 5728827 (1998-03-01), Thiruvengadam et al.
patent: 5739321 (1998-04-01), Wu et al.
patent: 5744467 (1998-04-01), McKittrick et al.
patent: 5756470 (1998-05-01), Yumibe et al.
patent: 5767115 (1998-06-01), Rosenblum et al.
patent: 5846966 (1998-12-01), Rosenblum et al.
patent: 5856473 (1999-01-01), Shankar
patent: 5886171 (1999-03-01), Wu et al.
patent: 5919672 (1999-07-01), Homann et al.
patent: 6093812 (2000-07-01), Thiruvengadam et al.
patent: 6096883 (2000-08-01), Wu et al.
patent: 6133001 (2000-10-01), Homann et al.
patent: 6207822 (2001-03-01), Thiruvengadam et al.
patent: RE37721 (2002-05-01), Rosenblum et al.
patent: 6426198 (2002-07-01), Carstea et al.
patent: 6593078 (2003-07-01), Altmann et al.
patent: 6627757 (2003-09-01), Fu et al.
patent: 6632933 (2003-10-01), Altmann et al.
patent: 7135556 (2006-11-01), Altmann et al.
patent: 2002/0151536 (2002-10-01), Davis et al.
patent: 2003/0125253 (2003-07-01), Taniyama et al.
patent: 2004/0093629 (2004-05-01), Altmann et al.
patent: 2004/0132058 (2004-07-01), Altmann et al.
patent: 2004/0137467 (2004-07-01), Altmann et al.
patent: 2004/0161838 (2004-08-01), Altmann et al.
patent: 2006/0035835 (2006-02-01), Taniyama et al.
patent: WO00/20623 (2000-04-01), None
patent: WO00/34240 (2000-06-01), None
patent: WO00/60107 (2000-10-01), None
patent: WO00/63703 (2000-10-01), None
patent: WO01/57190 (2001-08-01), None
patent: WO01/70974 (2001-09-01), None
patent: WO01/75067 (2001-10-01), None
patent: WO02/079174 (2002-10-01), None
patent: WO03/100094 (2003-12-01), None
patent: WO2004/009772 (2004-01-01), None
patent: WO2004/014947 (2004-02-01), None
patent: WO2004/032716 (2004-04-01), None
patent: WO2005/015988 (2005-02-01), None
patent: WO2005/069900 (2005-08-01), None
patent: WO2006/015365 (2006-02-01), None
Passarelli et al. (Diabetes Jul. 2005 vol. 54 No. 7 2198-2205).
Abstracts 1-79 from “The Second International Conference on Niemann-Pick Type C Disease”; May 29-31, 2003; Tuscon, Arizona.
Acton, et al., “Expression Cloning of SR-BI, a CD36-related Class B Scavenger Receptor”; The Journal of Biological Chemistry 269(33): 21003-21009 (1994).
Allayee, et al., “Biochemistry. An absorbing study of cholesterol”; Science. 290(5497):1709-1711 (2000).
Altmann, et al., “The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption.”; Biochim. Biophys. ACTA 1580: 77-93 (2002).
Altmann, et al., “Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption.”; Science. Feb. 20, 2004;303(5661):1201-1204.
Amigo, et al., “Relevance of Niemann-Pick Type C1 Protein Expression in Controlling Plasma Cholesterol and Biliary Lipid Secretion in Mice”; Hepatology 36(4): 819-828 (2002).
Berge, et al., “Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters”; Science 290(5497):1771-1775 (2000).
Blom, et al., “Defective endocytic trafficking of NPC1 and NPC2 underlying infantile Niemann-Pick type C disease”; Hum Mol Genet. Feb. 1, 2003;12(3):257-272.
Carstea, et al., “Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis”; Science 277:228-231 (1997).
Davies, et al., “Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1”; Genomics 65(2): 137-145 (2000).
Davies, et al., “Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia”; J. Biol. Chem. Apr. 1, 2005;280(13):12710-1220.
Davis, H.R., et al.; “The Synergistic Hypocholesterolemic Activity of the Potent Cholesterol Absorption Inhibitor, Ezetimibe, in combination with 3-hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors in Dogs”; Metabolism; 50(10):1234-1241 (2001).
Dawson, et al., “Intestinal cholesterol absorption”; Curr Opin Lipidol. 10(4):315-320 (1999).
Deninno, et al., “Steroidal glycoside cholesterol absorption inhibitors”; J. Med. Chem. 40(16):2547-2554 (1997).
Detmers, et al., “A target for cholesterol absorption inhibitors in the enterocyte brush border membrane”; Biochimica et Biophysica Acta 1486: 243-252 (2000).
Erickson, et al., “Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice.”; J. Inherit. Metab. Dis. Feb. 2000;23(1):54-62.
Erickson, et al., “Studies on neuronal death in the mouse model of Niemann-Pick C disease.”; J. Neurosci. Res. Jun. 15, 2002;68(6):738-744.
Erickson, et al., “mdr1a deficiency corrects sterility in Niemann-Pick C1 protein deficient female mice.”; Mol. Reprod. Dev. Jun. 2002;62(2):167-173.
Garcia-Calvo, Margarita, et al.; “The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)”; Proceedings of the National Academy of Sciences of the United States of America; 102(23):8132-8137 (2005).
Hauser, et al., “Identification of a Receptor Mediating Absorption of Dietary Cholesterol in the Intestine”; Biochemistry 37(51): 17843-17850 (1998).
Hawes, Brian, et al.; “In vivo responsiveness to exetimibe correlates with Niemann-Pick C1 like-1 (NPC1L1) binding affinity: Comparison of multiple species NPC1L1 orthologs”; Molecular Pharmacology; 71(1):19-29 (2007).
Hernandez, et al., “Intestinal absorption of cholesterol is mediated by a saturable, inhibitable transporter”; Biochimica et Biophysica Acta 1486: 232-242 (2000).
Ioannou, Yiannis A., “The structure and function of the Niemann-Pick C1 protein.”; Mol. Genet. Metab. 71(1-2): 175-181 (2000).
Ioannou, Yiannis A., “Multidrug permeases and subcellular cholesterol transport”; Nat Rev Mol Cell Biol. Sep. 2001;2(9):657-668.
Jourdheuil-Rahmani, et al., “Biliary anionic peptide fraction and apoA-I regulate intestinal cholesterol uptake”; Biochem Biophys Res Commun 292(2):390-395 (2002).
Kramer, et al., “Characterization and identification of the intestinal cholesterol uptake system”; Falk Symposium 129, Bile Acids: From Genomics to Disease and Therapy, 147-160 (2003).
Lipka, Leslie J.; “Ezetimibe: A first-in-class, novel cholesterol absorption inhibitor”; Cardiovascular Drug Reviews; 21(4):293-312 (2003).
Minhas, “Current Progress in Lipid Therapy”; Br. J. Cardiology 10(1): 59-68 (2003).
Reiss, P., et al.; “An enzymatic synthesis of glucuronides of azetidinone-based cholesterol absorption inhibitors”; Bioorganic & Medicinal Chemistry; 7(10):2199-2202 (1999).
Repa, et al., “Inhibition of cholesterol absorption by SCH 58053 in the mouse is not mediated via changes in the expression of mRNA for ABCA1, ABCG5, or ABCG8 in the enterocyte”; Journal of Lipid Research 43:1864-1874 (2002).
Rudel, Lawrence L.; “Preclinical and clinical pharmacology of a new class of lipid management agents”; The American Journal of Managed Care; 8(2):S33-S35 (2002).
Smart, et al., “Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transportȁ
Altmann Scott
Hawes Brian E.
O'Neill Kim Ann
Yao Xiaorui
Lee Jae W
Noakes Suzanne M
Schering Corporation
LandOfFree
NPC1L1 orthologues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NPC1L1 orthologues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NPC1L1 orthologues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675954